March 25 (Reuters) - Merck ( MRK ) said on Wednesday it
would buy biotech Terns Pharma in a deal valued at up
to $6.7 billion, as the drugmaker races to bolster its cancer
pipeline ahead of the looming patent loss for its blockbuster
therapy Keytruda.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Sriraj
Kalluvila)